Pharma News

Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and licensing antibody-drug conjugates (ADCs)...

Ozempic maker Novo Nordisk A/S took two large steps toward meeting demand for its blockbuster drugs, committing $1.2 billion to build a new factory in Denmark shortly after it got the green light for ...

Sangamo’s STAC-BBB is known for its ability to penetrate the blood-brain barrier and transduce neurons.

BioAge Labs has announced a multi-year research collaboration with Novartis – this partnership aims to identify and validate novel therapeutic drug targets by exploring the biological mechanisms und...

Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European Commission (EC) gave its approval in early December 2024.

Indian drugmakers Aurobindo, Glenmark and Zydus have issued separate sweeping drug recalls over issues pertaining to impurities and labeling. The product pulls were reported in a recent edition of the...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a preclinical drug.

Gilead Sciences has entered a strategic partnership with Terray Therapeutics for the discovery and development of small-molecule therapies across several targets. The partnership leverages Terray’s ...

SK biopharmaceuticals said Tuesday that it has signed a collaborative research and development agreement with Korean biotech company ProEn Therapeutics to develop radiopharmaceutical therapies (RP...

Sun Pharma Advanced Research Company (SPARC) signed a binding Letter of Intent (LoI) with the University of California, San Francisco (UCSF), and Tiller Therapeutics Inc. for a...

AbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim funding payments.

4D Molecular Therapeutics (FDMT) published landmark preclinical data in IOVS demonstrating the potential of its proprietary R100 vector and 4D-150 genetic medicine for treating neovascular ret...